Mark Hopman
Known title: Chief Commercial OfficerCIK: 0002048497
Associated companies
Transaction History
| BBNX | ▼ Sell | Open Market | 370 | $7K | 10/1/2026 | View on chart |
| BBNX | ▼ Sell | Open Market | 30,779 | $620K | 9/16/2026 | View on chart |
| BBNX | ▼ Sell | Open Market | 775 | $12K | 9/14/2026 | View on chart |
| BBNX | ▼ Sell | Open Market | 36,870 | $681K | 9/9/2026 | View on chart |
| BBNX | ▼ Sell | Open Market | 5,327 | $102K | 9/2/2026 | View on chart |
| BBNX | ▼ Sell | Open Market | 1,258 | $19K | 6/24/2026 | View on chart |
| BBNX | ▼ Sell | Open Market | 275 | $3K | 6/4/2026 | View on chart |
| BBNX | ▼ Sell | Open Market | 5,329 | $67K | 6/2/2026 | View on chart |
| BBNX | ▼ Sell | Open Market | 353 | $4K | 3/4/2026 | View on chart |
| BBNX | ▼ Sell | Open Market | 834 | $10K | 3/2/2026 | View on chart |
| BBNX | ▲ Buy | Grant | 109,105 | $0 | 2/27/2026 | View on chart |
| BBNX | ▼ Sell | Open Market | 2,061 | $63K | 12/4/2025 | View on chart |
| BBNX | ▼ Sell | Open Market | 856 | $25K | 12/2/2025 | View on chart |
| BBNX | ▲ Buy | Option Exercise | 11,411 | $58K | 9/5/2025 | View on chart |
| BBNX | ▼ Sell | Open Market | 11,411 | $235K | 9/5/2025 | View on chart |
| BBNX | ▲ Buy | Option Exercise | 656 | $3K | 9/4/2025 | View on chart |
| BBNX | ▲ Buy | Option Exercise | 4,093 | $21K | 9/4/2025 | View on chart |
| BBNX | ▼ Sell | Open Market | 6,818 | $136K | 9/4/2025 | View on chart |
| BBNX | ▼ Sell | Open Market | 848 | $16K | 9/2/2025 | View on chart |
| BBNX | ▲ Buy | Option Exercise | 16,158 | $82K | 8/19/2025 | View on chart |
| BBNX | ▼ Sell | Open Market | 16,158 | $268K | 8/19/2025 | View on chart |
| BBNX | ▼ Sell | Open Market | 238 | $4K | 6/2/2025 | View on chart |
| BBNX | ▼ Sell | Open Market | 551 | $10K | 6/2/2025 | View on chart |
| BBNX | ▼ Sell | Open Market | 79 | $1K | 6/2/2025 | View on chart |
| BBNX | ▲ Buy | Grant | 35,000 | $0 | 2/27/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Beta Bionics Signs Senseonics Deal, Gets New Analyst Coverage
Beta Bionics announced an agreement to integrate its iLet Bionic Pancreas with Senseonics' Eversense 365 sensor. This partnership aims to create a more comprehensive automated insulin delivery system. Additionally, Wells Fargo initiated coverage with an Overweight rating and a $28 price target, while Truist raised its target to the same level. The stock is currently trading within its 52-week range, with an average analyst target of $22.40.
Beta Bionics Signs Senseonics Deal, Gets New Analyst Coverage. Beta Bionics announced an agreement to integrate its iLet Bionic Pancreas with Senseonics' Eversense 365 sensor. This partnership aims to create a more comprehensive automated insulin delivery system. Additionally, Wells Fargo initiated coverage with an Overweight rating and a $28 price target, while Truist raised its target to the same level. The stock is currently trading within its 52-week range, with an average analyst target of $22.40.